Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05037747
Other study ID # YF2021-142
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date August 12, 2021
Est. completion date July 1, 2022

Study information

Verified date July 2022
Source Guangdong Provincial Hospital of Traditional Chinese Medicine
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Obesity is associated with glomerular hyperfiltration leading to renal impairment and is a risk factor for the progression of kidney disease.Weight loss can reduce proteinuria and improve eGFR.Intermittent fasting is safe and effective, and in addition to improving body shape and weight in obese patients, it can also improve glucolipid metabolism, reduce proteinuria, improve kidney function and delay the progression of kidney disease.


Description:

KDOQI clinical practice guideline for nutrition in chronic kidney disease (CKD) uses a low-protein diet to reduce renal impairment and delay progression. The current research hotspot is dietary intervention. Time-restricted feeding was used to intervene in the progression of CKD. It restrict the time of eating but not the eaten calories, which have a higher compliance and safety. Studies have shown that intermittent fasting in obese patients with CKD is not only reduce body weight, but also improves glycolipid metabolism, reduces proteinuria and delays the progression of kidney disease. Intermittent fasting is currently a scientific research hotspot, and there are few international studies on the implementation of intermittent fasting to delay the deterioration of renal function in obese CKD patients, and lack of data on Chinese patients, which has great research potential. Based on the above background, this study was conducted as an pilot clinical trial to explore the effects of intermittent fasting on obese patients with CKD and to observe its effectiveness, safety and compliance.


Recruitment information / eligibility

Status Completed
Enrollment 28
Est. completion date July 1, 2022
Est. primary completion date March 30, 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria: - Age 18-65 years - CKD stage 3-4 and not on dialysis (eGFR: 15-59ml/min/1.73m2) - BMI = 25 kg/m2 - Good reading and comprehension skills, simple smartphone operation and no communication difficulties - Signed informed consent Exclusion Criteria: - Pregnant and breastfeeding - End-stage diseases - Acute and active diseases such as gastrointestinal bleeding or acute infections, serious decompensation with diseases such as cirrhosis decompensation stage, malignant tumor, serious heart and lung diseases, severe primary diseases of hematopoietic system, severe hypertension (systolic blood pressure =200mmHg, diastolic blood pressure =120mmHg) and difficult to control blood pressure, within 3 months after major surgery, such as open surgery - Mental patients - Using medium-high doses of hormones and immunosuppressants - Participating in other researchers - Taking other dietary therapies, undergoing weight loss treatment - Vegetarian - Type 1 diabetes and type 2 diabetes using insulin

Study Design


Intervention

Behavioral:
Time-restricted feeding(TRF)
The TRF group was asked to restrict the eating window to 8 hours a day, during waking hours and also continue a low-protein diet.

Locations

Country Name City State
China Guangdong Provincial Hospital of Chinese Medicine Guangzhou Guangdong

Sponsors (1)

Lead Sponsor Collaborator
Guangdong Provincial Hospital of Traditional Chinese Medicine

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Other Changes in hunger scores Assessed using Visual Analog Scales (VAS with a scale of 1-10) Weeks 6 and 12
Other Changes in fatigue scores Assessed using Visual Analog Scales (VAS with a scale of 1-10) Weeks 6 and 12
Other Changes in satiety scores Assessed using Visual Analog Scales (VAS with a scale of 1-10) Weeks 6 and 12
Other Changes in gastrointestinal flatulence scores Assessed using Visual Analog Scales (VAS with a scale of 1-10) Weeks 6 and 12
Other Changes in nausea and vomiting scores Assessed using Visual Analog Scales (VAS with a scale of 1-10) Weeks 6 and 12
Other Changes in constipation scores Assessed using Visual Analog Scales (VAS with a scale of 1-10) Weeks 6 and 12
Other Changes in diarrhea scores Assessed using Visual Analog Scales (VAS with a scale of 1-10) Weeks 6 and 12
Other Changes in dry mouth and bitterness scores Assessed using Visual Analog Scales (VAS with a scale of 1-10) Weeks 6 and 12
Other Changes in dizziness and headache scores Assessed using Visual Analog Scales (VAS with a scale of 1-10) Weeks 6 and 12
Other Changes in irritability scores Assessed using Visual Analog Scales (VAS with a scale of 1-10) Weeks 6 and 12
Other Changes in anxiety scores Assessed using Visual Analog Scales (VAS with a scale of 1-10) Weeks 6 and 12
Other Changes in depression scores Assessed using Visual Analog Scales (VAS with a scale of 1-10) Weeks 6 and 12
Primary Change in eGFR (ml/min/1.73m2) eGFR at final visit - eGFR at initial visit 12 weeks
Secondary Changes in body weight (Kilograms) body weight at final visit - body weight at initial visit 12 weeks
Secondary Changes in waist circumference (cm) waist circumference at final visit - waist circumference at initial visit 12 weeks
Secondary Change in body mass index (kg/m2) body mass index at final visit - body mass index at initial visit 12 weeks
Secondary Changes in serum total cholesterol levels (mmol/L) serum total cholesterol levels at final visit - serum total cholesterol levels at initial visit 12 weeks
Secondary Changes in serum low density lipoprotein cholesterol levels (mmol/L) serum low density lipoprotein cholesterol levels at final visit - serum low density lipoprotein cholesterol levels at initial visit 12 weeks
Secondary Changes in serum triglyceride levels (mmol/L) serum triglyceride levels at final visit - serum triglyceride levels at initial visit 12 weeks
Secondary Changes in serum high density lipoprotein cholesterol levels (mmol/L) serum high density lipoprotein cholesterol levels at final visit - serum high density lipoprotein cholesterol levels at initial visit 12 weeks
Secondary Changes in serum albumin (g/L) serum albumin at final visit - serum albumin at initial visit 12 weeks
Secondary Changes in total serum protein (g/L) total serum protein at final visit - total serum protein at initial visit 12 weeks
Secondary Changes in fat free mass (kg) fat free mass at final visit - fat free mass at initial visit 12 weeks
Secondary Changes in body fat mass (kg) body fat mass at final visit - body fat mass at initial visit 12 weeks
Secondary Changes in percent body fat (%) percent body fat at final visit - percent body fat at initial visit 12 weeks
Secondary Changes in waist-hip ratio waist-hip ratio at final visit - waist-hip ratio at initial visit 12 weeks
Secondary Changes in soft lean mass (kg) soft lean mass at final visit - soft lean mass at initial visit 12 weeks
Secondary Changes in visceral fat area (cm2) visceral fat area at final visit - visceral fat area at initial visit 12 weeks
Secondary Changes in arm circumference (cm) arm circumference at final visit - arm circumference at initial visit 12 weeks
Secondary Changes in triceps skin fold thickness (cm) triceps skin fold thickness at final visit - triceps skin fold thickness at initial visit 12 weeks
Secondary Changes in grip strength (kg) grip strength at final visit - grip strength at initial visit 12 weeks
Secondary Changes in fasting blood glucose (mmol/L) fasting blood glucose at final visit - fasting blood glucose at initial visit 12 weeks
Secondary Changes in serum creatinine (umol/L) serum creatinine at final visit - serum creatinine at initial visit 12 weeks
Secondary Changes in blood urea nitrogen (mmol/L) blood urea nitrogen at final visit - blood urea nitrogen at initial visit 12 weeks
Secondary Changes in serum uric acid (umol/L) serum uric acid at final visit - serum uric acid at initial visit 12 weeks
Secondary Changes in proteinuria creatinine ratio (g/g) proteinuria creatinine ratio at final visit - proteinuria creatinine ratio at initial visit 12 weeks
Secondary Changes in serum cystatin C (mg/L) serum cystatin C at final visit - serum cystatin C at initial visit 12 weeks
Secondary Changes in total urine urea in 24 hours (mmol/24h) total urine urea in 24 hours at final visit - total urine urea in 24 hours at initial visit 12 weeks
Secondary Changes in interleukin-6 (pg/mL) interleukin-6 at final visit - interleukin-6 at initial visit 12 weeks
Secondary Changes in tumor necrosis factor-a (pg/mL) tumor necrosis factor-a at final visit - tumor necrosis factor-a at initial visit 12 weeks
Secondary Changes in C-reactive protein (mg/L) C-reactive protein at final visit - C-reactive protein at initial visit 12 weeks
Secondary Changes in species of intestinal flora species of intestinal flora at final visit - species of intestinal flora at initial visit 12 weeks
See also
  Status Clinical Trial Phase
Recruiting NCT04243317 - Feasibility of a Sleep Improvement Intervention for Weight Loss and Its Maintenance in Sleep Impaired Obese Adults N/A
Recruiting NCT04101669 - EndoBarrier System Pivotal Trial(Rev E v2) N/A
Terminated NCT03772886 - Reducing Cesarean Delivery Rate in Obese Patients Using the Peanut Ball N/A
Completed NCT03640442 - Modified Ramped Position for Intubation of Obese Females. N/A
Completed NCT04506996 - Monday-Focused Tailored Rapid Interactive Mobile Messaging for Weight Management 2 N/A
Recruiting NCT06019832 - Analysis of Stem and Non-Stem Tibial Component N/A
Active, not recruiting NCT05891834 - Study of INV-202 in Patients With Obesity and Metabolic Syndrome Phase 2
Active, not recruiting NCT05275959 - Beijing (Peking)---Myopia and Obesity Comorbidity Intervention (BMOCI) N/A
Recruiting NCT04575194 - Study of the Cardiometabolic Effects of Obesity Pharmacotherapy Phase 4
Completed NCT04513769 - Nutritious Eating With Soul at Rare Variety Cafe N/A
Withdrawn NCT03042897 - Exercise and Diet Intervention in Promoting Weight Loss in Obese Patients With Stage I Endometrial Cancer N/A
Completed NCT03644524 - Heat Therapy and Cardiometabolic Health in Obese Women N/A
Recruiting NCT05917873 - Metabolic Effects of Four-week Lactate-ketone Ester Supplementation N/A
Active, not recruiting NCT04353258 - Research Intervention to Support Healthy Eating and Exercise N/A
Completed NCT04507867 - Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III N/A
Recruiting NCT03227575 - Effects of Brisk Walking and Regular Intensity Exercise Interventions on Glycemic Control N/A
Completed NCT01870947 - Assisted Exercise in Obese Endometrial Cancer Patients N/A
Recruiting NCT05972564 - The Effect of SGLT2 Inhibition on Adipose Inflammation and Endothelial Function Phase 1/Phase 2
Recruiting NCT06007404 - Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
Recruiting NCT05371496 - Cardiac and Metabolic Effects of Semaglutide in Heart Failure With Preserved Ejection Fraction Phase 2